Vanguard Global Advisers
RNA

Vanguard Global Advisers’s Atrium Therapeutics RNA Stock Holding History

Vanguard Global Advisers’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.1K Hold
5,585
– – ﹤0.01% 2911
2026
Q1 		$74.7K Buy
+5,585
New +$78.5K ﹤0.01% 2849

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Global Advisers's RNA Position: Q2 2026 in Review

Vanguard Global Advisers held its Atrium Therapeutics (RNA) position steady in Q2 2026 at 5,585 shares worth $75.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Vanguard Global Advisers first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Vanguard Global Advisers held 5,585 shares of Atrium Therapeutics worth $75.1K as of Q2 2026.
  • Vanguard Global Advisers left its Atrium Therapeutics share count unchanged in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2911 holding.
  • Vanguard Global Advisers first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.